Rezolute, Inc.
RZLTHealthcare|Biotechnology|US
$3.88
+0.24 (+6.59%)
DCF Value
$0.05
Tangible Book / Share
$0.82
Cash / Share
$0.86
About
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Stock Price
-59.6%(1Y)
1M
-16.4%
3M
-17.3%
6M
+20.9%
YTD
+64.4%
1Y
-61.0%
3Y
+288.0%
5Y
-41.6%
Pipeline Summary
5 total trials0
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
Completed: 2Active: 1Available: 1Recruiting: 1
Active Trials (2)
RZ358 Treatment for Congenital Hyperinsulinism
NCT06208215Congenital Hyperinsulinism
Phase 3Active
Enrollment: 56 participants
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
NCT06881992Tumor Hyperinsulinism (Tumor HI)
Phase 3Recruiting
Enrollment: 16 participants
Key Facts
Market Cap$375.3M
Employees58 (-18% YoY)
CEONevan Charles Elam
IPO DateJan 14, 2013
Beta0.62
52-Week Range$1.07 – $11.46
Avg Volume1,472,676
ExchangeNASDAQ
Websiterezolutebio.com
Ownership
Float62.8%
Shares Outstanding96.7M
Recent Insider Trades
Evans DaronGIFT
Oct 21, 202616,000 shares
Evans DaronGIFT
Oct 21, 20264,000 shares
Karnawat Sunil RatilalTAX W/H
Sep 2, 20262,267 shares @ $4.50
ROBERTS BRIAN KENNETHTAX W/H
Jul 2, 20263,062 shares @ $4.99
Elam Nevan CTAX W/H
Jul 2, 20268,004 shares @ $4.99
Peers
Recent News
Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update
Nov 5, 2026 · globenewswire.com
Rezolute (NASDAQ:RZLT) Share Price Breaks Above 200 Day Moving Average – Here’s What Happened
Nov 4, 2026 · defenseworld.net
Rezolute to Participate in Upcoming Investor Conferences
Nov 2, 2026 · globenewswire.com
Rezolute (NASDAQ:RZLT) Stock Price Crosses Below 200-Day Moving Average – What’s Next?
Oct 27, 2026 · defenseworld.net
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Oct 14, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:32 AM